Member Info for Coffee73

What am I missing. Value of �31m, �9m in cash and profit �6m. Why is this share price so low?

interesting read. Bodes well for the future: http://www.tpgroup.uk.com/about-us/news/2017/08/first-component-machined-tpgs-adva

Anybody explain why the price fell so much after the results. Thought they were good (apart from the southern area) with a higher than last year future order book and an increase in the divi. Are things really that bad that justifies a fall of 10%?

Great trading update but thought we would have had a bigger uptick on the price. 18% growth at constant currency and 39% growth with currency cannot be sniffed at. As most of their sales are in the first half and sterling still low the future looks good for this year and that's without any progress in USA. Think this is a good share with good organic sales plus potential new product pipeline that could be huge. Keep the faith and dyor.

Here's hoping for a positive trading update.

http://hardmanandco.com/docs/default-source/company-docs/allergy-therapeutics-documents/26.09.16-excellent-performance-drives-market-share-gains.pdf

http://hardmanandco.com/docs/default-source/company-docs/allergy-therapeutics-documen

Think you have miss understood. The sell quote was 10.05 and the buy was 10.7. I think the spread seen above is not that accurate. I wonder when we will get any news.

Your right just got a quote to buy at 10.7 and sell at 10.05 so not too bad. do I top up to reduce my average cost or hold for some news. The question is what should I be looking / waiting for.

Would you buy with this spread?

Anybody know why today's rise. Not complaining just wondering.

Anybody know why the high volume of trades today?

I agree. Good set of results with plenty of positive news for the future (additional sales offices in USA plus opening up in Austrialia) and yet the price doesn't move. Ok the good news was expected and therefore priced in but would have thought there would have been an uptick in the price given the fact sales should continue to grow strongly; especially from abroad; during the next financial year.

I agree. I think the fact that they have made an upfront payment shows the technology works and has a significant advantage over current methods. Hopefully this should help other pharma companies take notice and will certainly encourage other researchers to at least trial the affirmers. I wonder what the update in August will show.

https://www.crackit.org.uk/affimers-animal-free-alternatives-antibodies Avacta Life Sciences are reducing animal use in the biosciences through the production of Affimers. Affimers are an antibody alternative that are produced wholly in vitro, thus negating the need for animals. In support of these principles we have recently partnered with NC3Rs, the UK-based scientific organisation dedicated to the replacement, reduction and refinement of animal use in research and testing. NC3Rs are now offering funding through their commercial innovation platform CRACK IT for collaborative partners who wish to utilise Affimers within their own research in the place of antibodies or for testing Affimers in new applications and platforms. Applications for funding your research using Affimers can be made at any time within the next six months and can support projects for up to 12 months, using either off-the-shelf Affimers or bespoke Affimer reagents generated through custom screens.

I think this deal shows Affirmers have a bright future and I hope start to replace antibodies as the research tool of choice. Antibodies unreliable conduit for research but still dominate a market worth $50 billion. I like the comment tens of millions $ potential from this deal alone. And to think I was starting to loose the faith.

Can't make up my mind about last year. Good news is that Affirmers seem to be getting repeat business and sales are growing strongly bearing in mind they were only introduced 3rd quarter last year and its new technology. Bad news no mention of sensipod and the loss of a big contract. Agree with last comment this year will show whether or not Affirmers will take off. Fingers crossed

http://www.ddw-online.com/winter-14-full-articles/p274236-restucturing-proteomics:-the-rise-of-next-generation-affinity-reagents.html

What a week

Seems to be a head of steam building around the Affirmers with a few ties ups announced over the last few months. Shows that other pharma companies think the Affirmers have promise. Just need to see this translate into revenue. Fingers crossed.